View Filter All NewsPress Release Years All Years20202019201820172016201520142013201220112010 Apply Press Release | October 29, 2020 Vertex Reports Third-Quarter 2020 Financial Results READ MORE Press Release | October 14, 2020 Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency READ MORE Press Release | September 25, 2020 FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age READ MORE Press Release | September 24, 2020 Vertex Receives CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) in Combination with KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 6-11 Years with Certain Mutations in the CFTR gene READ MORE Pagination Current page 1 Page 2 Page 3 Next page Next
